Merck & Co. shares slipped in the extended session Monday after the drug maker said its cancer treatment Keytruda failed to meet clinical endpoints in...
Merck shares slip as Keytruda fails another clinical trial - MarketWatch
Words
0
Reading
0 min
Listen
Play
2019-05-20 22:37